Global Blood Therapeutics (GBT) Reports In-Line Q3 Loss

November 9, 2016 4:12 PM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Global Blood Therapeutics (NASDAQ: GBT) reported Q3 EPS of ($0.58), in-line with the analyst estimate of ($0.58).

Cash and cash equivalents totaled $217.8 million at September 30, 2016, compared with $148.5 million at December 31, 2015.

For earnings history and earnings-related data on Global Blood Therapeutics (GBT) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities